title: [Mitral valve replacement with the Björk-Shiley monostrut prosthesis: a 4-year clinical experience].
abstract: Mitral valve replacement with Björk-Shiley monostrut prostheses was performed in 142 patients, aged 18 to 73 (mean age: 53.8). A group of 101 patients underwent isolated mitral replacement (group A), while both mitral and aortic (in one case tricuspid) valves were replaced in 41 (group B). In 19 of group A patients and in 9 of group B patients a tricuspid annuloplasty was added. Hospital mortality was one case in each group (group A: 1%; group B:2.4%). The cause of death was low output in both cases (i.e. not valve-related). Late mortality occurred in 4 cases (4%) in group A, and in 3 cases (7.3%) in group B (follow-up: 6 to 58 months; mean follow-up: 24 months). Actuarial survival was 93.79% in group A and 89.94% in group B one year after surgery; it was 93.79% in group A and 81.76% in group B after 3 years. All deaths from undetermined causes, as well as any new unexplained neurological deficit or peripheral emboli, were considered to be valve-related: 84.18% of group A patients, as well as 67.90% of group B, were event free after 3 year (actuarial). most valve-related events occurred in the first year after surgery. We observed thromboembolism in 3 cases for each group: one patient in group B had pannus formation over the prosthetic annulus; prosthetic valve endocarditis in 1 case of group A and 2 of group B; significant hemorrhage due to anticoagulant therapy in 1 (group A); one patient in each group died suddenly, 4 and 7 months postoperatively. One group A patient and 2 group B patients were reoperated: a new valve prosthesis was implanted in two patients. Mean transvalvular gradient, as determined by echocardiography, was 3.8 +/- 2.3 (SD) mmHg in the case of isolated mitral replacement. In conclusion, we believe these results are highly encouraging, especially in the isolated mitral replacement group. Björk-Shiley monostrut prosthesis has been demonstrated to be a reliable valve substitute, with an acceptable incidence of complications. No Björk-Shiley monostrut prosthesis structural deterioration was seen, and its hemodynamic behaviour may be considered satisfactory.
authors.affiliation: Dipartimento di Cardiochirurgia, Policlinico di Careggi, Firenze.
authors.forename: F
authors.initials: F
authors.lastname: Alajmo
authors.forename: A M
authors.initials: AM
authors.lastname: Perna
authors.forename: G
authors.initials: G
authors.lastname: Calamai
authors.forename: R
authors.initials: R
authors.lastname: Nigro
authors.forename: M
authors.initials: M
authors.lastname: Cassai
authors.forename: G
authors.initials: G
authors.lastname: Montesi
authors.forename: L
authors.initials: L
authors.lastname: Braconi
authors.forename: A
authors.initials: A
authors.lastname: Borgioli
authors.forename: M
authors.initials: M
authors.lastname: Preziuso
authors.forename: A
authors.initials: A
authors.lastname: Palminiello
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000368:Aged; D004452:Echocardiography; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D013997:Time Factors
vernacular_title: Sostituzione valvolare mitralica con la protesi Björk-Shiley monostrut. Esperienza clinica di 4 anni.